1,693
Views
8
CrossRef citations to date
0
Altmetric
Original Research

The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence

ORCID Icon, &
Pages 145-152 | Published online: 18 Jan 2022

Figures & data

Table 1 Demographics

Figure 1 Responses to the question, “How much do you notice glare or halos around lights in dim light situation?” suggest that patients implanted with Vivity IOLs were significantly less likely to notice glare and halos more than “just a little” and significantly more likely not to notice these symptoms at all compared to all other IOL cohorts. (p<0.02 vs Panoptix, p<0.03 vs 2.5/3.0 and 2.5 mini-mono, Chi squared test).

Figure 1 Responses to the question, “How much do you notice glare or halos around lights in dim light situation?” suggest that patients implanted with Vivity IOLs were significantly less likely to notice glare and halos more than “just a little” and significantly more likely not to notice these symptoms at all compared to all other IOL cohorts. (p<0.02 vs Panoptix, p<0.03 vs 2.5/3.0 and 2.5 mini-mono, Chi squared test).

Figure 2 Frequency of spectacle use.

Figure 2 Frequency of spectacle use.

Table 2 Patient-Reported Spectacle Dependence (Response to the Question, “Do You Ever Need to Use Spectacles for the Following Activities?”)

Figure 3 Satisfaction ratings of the Vivity lens were similar to other lenses among patients responding “very satisfied” or “satisfied”. Significantly more patients responded “very satisfied” to the Panoptix lens compared to all others.

Figure 3 Satisfaction ratings of the Vivity lens were similar to other lenses among patients responding “very satisfied” or “satisfied”. Significantly more patients responded “very satisfied” to the Panoptix lens compared to all others.

Figure 4 All four groups had very good refractive accuracy. Compared to the Vivity, 2.5/3.0, and 2.5 mini-monovision cohorts, the PanOptix cohort had significantly higher refractive accuracy among patients within 0.25 and 0 diopters of emmetropia (P< 0.0001, chi-squared test for both groups).

Figure 4 All four groups had very good refractive accuracy. Compared to the Vivity, 2.5/3.0, and 2.5 mini-monovision cohorts, the PanOptix cohort had significantly higher refractive accuracy among patients within 0.25 and 0 diopters of emmetropia (P< 0.0001, chi-squared test for both groups).